Antithrombotic therapy in peripheral artery disease

Vasc Med. 2016 Apr;21(2):156-69. doi: 10.1177/1358863X15622987. Epub 2016 Jan 28.

Abstract

Antiplatelet agents are recommended for the reduction of major adverse cardiovascular events among all patients with symptomatic peripheral artery disease. However, the optimal antiplatelet regimen and duration of therapy in peripheral artery disease (PAD) remains unclear, largely due to limited and conflicting data in this patient population. This article reviews current data on antithrombotic therapy in PAD and discusses the implications of this data for current practice and future research.

Keywords: anticoagulants; arterial occlusive diseases; critical limb ischemia; intermittent claudication; peripheral artery disease; platelet aggregation inhibitors.

Publication types

  • Review

MeSH terms

  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Blood Coagulation / drug effects
  • Critical Illness
  • Drug Therapy, Combination
  • Fibrinolytic Agents / adverse effects
  • Fibrinolytic Agents / therapeutic use*
  • Hemorrhage / chemically induced
  • Humans
  • Intermittent Claudication / blood
  • Intermittent Claudication / diagnosis
  • Intermittent Claudication / drug therapy*
  • Intermittent Claudication / mortality
  • Ischemia / blood
  • Ischemia / diagnosis
  • Ischemia / drug therapy*
  • Ischemia / mortality
  • Peripheral Arterial Disease / blood
  • Peripheral Arterial Disease / diagnosis
  • Peripheral Arterial Disease / drug therapy*
  • Peripheral Arterial Disease / mortality
  • Platelet Aggregation / drug effects
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Risk Factors
  • Treatment Outcome

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors